Comparison of topical methotrexate and topical tazarotene in psoriasis vulgaris
Not Applicable
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2023/10/059038
- Lead Sponsor
- Government Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Patients of more than 18 years of age with clinical diagnosis of psoriasis vulgaris with
PASI(Psoriasis area severity index) <10.
2) Patients having bilateral skin lesions.
3) Patients who are not desirous of conception during the study period.
Exclusion Criteria
1) Pregnant or lactating mothers.
2) Patients having any systemic illness.
3)Patients with flexural psoriasis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of 1% topical methotrexate and 0.1% topical tazarotene in <br/ ><br>treatment of psoriasis vulgaris using PASI and mPASI scores at 2 weekly interval for 8 weeksTimepoint: 0,2,4,6,8 weeks
- Secondary Outcome Measures
Name Time Method To assess the adverse effects with both the topical therapiesTimepoint: 0,2,4,6,8 weeks